April 7, 2014
by Endia Vereen
JURIST Guest Columnist Kristen Swift, Widener University School of Law Class of 2014, discusses Merck & Co.'s NuvaRing settlement and the company's corporate governance policies...Recently, Merck & Co. made a major splash across headlines by offering NuvaRing plaintiff's a $100 million ...[read more]
March 22, 2014
by Endia Vereen
JURIST Guest Columnist Melissa Brumer Fordham University School of Law Class of 2015, discusses the differences in settlement amounts between recent contraceptive lawsuits and argues that Merck may be getting out much more cheaply than its competitors...On Friday, February 7, 2014, Merck & Co... ...[read more]
March 5, 2014
by Endia Vereen
JURIST Guest Columnist Tara Pakrouh, Widener University School of Law Class of 2015, discusses Merck & Co.'s $100 million settlement concerning the corporation's NuvaRing contraceptive device, the board's liability and the fiduciary duties it owes to its shareholders...In a December 2000 email ...[read more]
February 8, 2014
by Matthew Pomy
Merck & Co. agreed to pay $100 million to settle thousands of lawsuits concerning Merck's NuvaRing contraceptive device. The lawsuits allege that NuvaRing potentially causes fatal blood clots. The settlement will provide an average payment of over $58,000 per case. This settlement is less than ...[read more]
May 29, 2012
by Garrett Eisenhour
On May 29, 2008, a Texas state appeals court overturned a $26 million jury verdict against pharmaceutical giant Merck awarded to widow Carol Ernst, who alleged that her husband died after taking painkiller Vioxx. That same day, the New Jersey Appellate Division reduced a jury award in a separate ...[read more]
November 23, 2011
by Jamie Reese
Merck & Co reached a settlement agreement Tuesday with the US Department of Justice (DOJ), agreeing to pay $950 million in criminal and civil penalties. The agreement includes $321 million in criminal fines and $628 million in civil fines as well as submitting a guilty plea to an information ...[read more]
June 30, 2010
by Patrice Collins
A judge for the US District Court for the Eastern District of Louisiana on Tuesday ruled in favor of Merck & Co. in a lawsuit filed by the state of Louisiana over reimbursements for the prescription painkiller Vioxx. Louisiana had argued that it would have restricted the sales of Vioxx ...[read more]
April 27, 2010
by Jaclyn Belczyk
The US Supreme Court on Tuesday allowed a suit to proceed against drug maker Merck & Co. over the safety record of its painkiller Vioxx. The court ruled unanimously in Merck & Co. v. Reynolds that the statute of limitations in a securities fraud lawsuit begins to run once the plaintiff ...[read more]
April 27, 2010
by Jaclyn Belczyk
The US Supreme Court on Tuesday allowed a suit to proceed against drug maker Merck & Co. over the safety record of its painkiller Vioxx. The court ruled unanimously in Merck & Co. v. Reynolds that the statute of limitations in a securities fraud lawsuit begins to run once the plaintiff ...[read more]
September 30, 2009
by JURIST Staff
On September 30, 2004, the pharmaceutical company, Merck, pulled its arthritis drug, Vioxx from the worldwide market, due to strokes and heart attacks in patients, but the move did not stop over 45,000 former-users and their families from suing Merck. The plaintiffs, however, have struggled to ...[read more]

Support JURIST

We rely on our readers to keep JURIST running

 Donate now!

© Copyright JURIST Legal News and Research Services, Inc., 2013.